Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B
- PMID: 19793171
- DOI: 10.1111/j.1440-1746.2009.05953.x
Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B
Abstract
Background and aim: Recently, various non-invasive blood markers and indices have been studied to overcome the limitations of liver biopsy, such as its invasiveness and sampling errors. However, the majority of these studies have focused on patients with chronic hepatitis C. Accordingly, this study was performed to evaluate the significances of various non-invasive serum markers in terms of predicting the presence of liver cirrhosis in chronic hepatitis B.
Methods: We included 125 chronic hepatitis B patients who had undergone liver biopsy. Fibrosis stage was assessed using the METAVIR scoring system (F0-F4), which defines liver cirrhosis as F4. In addition, we measured various blood markers at times of liver biopsy.
Results: Thirty four of the 125 patients (27.2%) were rated as F4 by liver biopsy. Age, platelet, white blood cells, aspartate aminotransferase (AST), alanine aminotransferase, haptoglobin, apolipoprotein-A1 (Apo-A1), collagen-IV, hyaluronic acid, alpha2-macroglobulin, matrix metalloproteinase-2, and YKL-40 were significantly different between patients with chronic hepatitis and those with liver cirrhosis. However, multivariate analysis showed that only platelet, AST, haptoglobin, and Apo-A1 independently predicted the presence of liver cirrhosis. Having identified these four factors, we devised a system, which we refer to as platelet count, AST, haptoglobin, and Apo-A1 (PAHA). The area under the receiver-operating characteristics (AUROC) of PAHA indices for the presence of liver cirrhosis was 0.924 (95% confidence interval, 0.877-0.971), which was significantly greater than the AUROC of other indices of fibrosis.
Conclusion: The devised PAHA system was found to be useful for predicting the presence of liver cirrhosis in patients with chronic hepatitis B.
Comment in
-
PAHA model: an alternative non-invasive predictor of liver cirrhosis in patients with chronic hepatitis B infection.J Gastroenterol Hepatol. 2010 Jan;25(1):3-4. doi: 10.1111/j.1440-1746.2009.06041.x. J Gastroenterol Hepatol. 2010. PMID: 20136968 No abstract available.
Similar articles
-
PAHA model: an alternative non-invasive predictor of liver cirrhosis in patients with chronic hepatitis B infection.J Gastroenterol Hepatol. 2010 Jan;25(1):3-4. doi: 10.1111/j.1440-1746.2009.06041.x. J Gastroenterol Hepatol. 2010. PMID: 20136968 No abstract available.
-
[Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease].Korean J Hepatol. 2009 Dec;15(4):454-63. doi: 10.3350/kjhep.2009.15.4.454. Korean J Hepatol. 2009. PMID: 20037264 Korean.
-
Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B.Liver Int. 2007 Sep;27(7):969-76. doi: 10.1111/j.1478-3231.2007.01519.x. Liver Int. 2007. PMID: 17696936
-
Noninvasive methods to assess liver disease in patients with hepatitis B or C.Gastroenterology. 2012 May;142(6):1293-1302.e4. doi: 10.1053/j.gastro.2012.02.017. Gastroenterology. 2012. PMID: 22537436 Review.
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.Am J Gastroenterol. 2014 Jun;109(6):796-809. doi: 10.1038/ajg.2014.21. Epub 2014 Feb 18. Am J Gastroenterol. 2014. PMID: 24535095 Review.
Cited by
-
Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease.Sci Rep. 2016 Oct 14;6:35282. doi: 10.1038/srep35282. Sci Rep. 2016. PMID: 27739482 Free PMC article.
-
YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?Cancers (Basel). 2010 Jul 12;2(3):1453-91. doi: 10.3390/cancers2031453. Cancers (Basel). 2010. PMID: 24281168 Free PMC article.
-
Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.Cancer Med. 2020 May;9(9):3057-3069. doi: 10.1002/cam4.2968. Epub 2020 Mar 9. Cancer Med. 2020. PMID: 32150664 Free PMC article.
-
Hyaluronic acid inhibition by 4-methylumbelliferone reduces the expression of cancer stem cells markers during hepatocarcinogenesis.Sci Rep. 2019 Mar 11;9(1):4026. doi: 10.1038/s41598-019-40436-6. Sci Rep. 2019. PMID: 30858465 Free PMC article.
-
Potential of Apolipoprotein A1 (ApoA1) for Detecting Liver Cirrhosis and Hepatocellular Carcinoma.Asian Pac J Cancer Prev. 2022 Jun 1;23(6):2001-2008. doi: 10.31557/APJCP.2022.23.6.2001. Asian Pac J Cancer Prev. 2022. PMID: 35763642 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous